Capricor Therapeutics Stock Plummets 67% as FDA Questions DMD Drug Efficacy

Key Facts

In a move that underscores the biotech sector's extreme sensitivity to regulatory shifts, Capricor Therapeutics shares experienced a massive sell-off, plunging 67.7%. This collapse followed the release of FDA briefing documents that questioned the efficacy of deramiocel, the company's treatment for Duchenne muscular dystrophy (DMD). According to reports, the regulatory body raised significant concerns regarding the analysis of clinical trial data, severely damaging investor confidence in the drug's approval prospects.

This sharp decline comes ahead of a pivotal FDA Advisory Committee meeting scheduled for July 29 to review the drug's Biologics License Application. The briefing documents noted that data from the HOPE-3 study, when considered alongside previous results, failed to provide substantial evidence of effectiveness, characterizing changes in muscle and cardiac function as small, variable, and statistically insignificant. In response, the company defended its results, stating they were governed by a finalized analysis plan established prior to unblinding.

Traders should closely watch the outcome of the FDA Advisory Committee meeting on July 29, as the decision will serve as a primary catalyst for the stock's future trajectory. Additionally, the market is awaiting broader economic catalysts, such as the UK Consumer Price Index data due on July 22, 2026, which may influence general risk appetite in the growth sector.